Overexpression of sphingosine-1-phosphate receptors on reactive astrocytes drives neuropathology of multiple sclerosis rebound after fingolimod discontinuation

We present the neuropathological description of an autoptic case of fatal rebound of disease activity after fingolimod discontinuation in a multiple sclerosis patient. MRI prior to the fatal outcome showed several large tumefactive demyelinating lesions. These lesions were characterized by prominent astrocytic gliosis, with a remarkable preponderance of large hypertrophic reactive astrocytes showing intense expression of sphingosine-1-phosphate receptor 1. Prominent astrocytic gliosis was also diffusely observed in the normal-appearing white matter. Dysregulated sphingosine-1-phosphate signaling on astrocytes following fingolimod withdrawal might represent a possible contributing mechanism to disease rebound and might account for the unusual radiological and neuropathological features observed in the present case.

[1]  A. Ghezzi,et al.  Dramatic rebounds of MS during pregnancy following fingolimod withdrawal , 2017, Neurology: Neuroimmunology & Neuroinflammation.

[2]  E. Waubant,et al.  Rebound Syndrome in Patients With Multiple Sclerosis After Cessation of Fingolimod Treatment. , 2016, JAMA neurology.

[3]  R. Siripurapu,et al.  Severe tumefactive rebound of multiple sclerosis following fingolimod cessation , 2016, BMJ Case Reports.

[4]  C. Tan International consensus diagnostic criteria for neuromyelitis optica spectrum disorders , 2016, Neurology.

[5]  A. Lapucci,et al.  Dysregulation of sphingosine 1 phosphate receptor-1 (S1P1) signaling and regulatory lymphocyte-dependent immunosuppression in a model of post-fingolimod MS rebound , 2015, Brain, Behavior, and Immunity.

[6]  R. Gold,et al.  Tumefactive multiple sclerosis lesions in two patients after cessation of fingolimod treatment , 2015, Therapeutic advances in neurological disorders.

[7]  Niklas Luetzen,et al.  Severe disease reactivation in four patients with relapsing–remitting multiple sclerosis after fingolimod cessation , 2015, Journal of Neuroimmunology.

[8]  I. Lotan,et al.  Tumefactive demyelination and a malignant course in an MS patient during and following fingolimod therapy , 2014, Journal of the Neurological Sciences.

[9]  J. Newcombe,et al.  Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide , 2014, Annals of neurology.

[10]  M. Amato,et al.  Withdrawal of fingolimod treatment for relapsing–remitting multiple sclerosis: report of six cases , 2012, Multiple sclerosis.

[11]  R. Hohlfeld,et al.  Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment. , 2012, Archives of neurology.

[12]  W. Brück,et al.  Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis , 2008, Brain : a journal of neurology.